Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:41:54 EDT Fri 16 Oct 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:TRAW from 2025-10-17 to 2026-10-16 - 15 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-08-14 16:30U:TRAWNews ReleaseTraws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
2026-06-22 07:00U:TRAWNews ReleaseTraws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
2026-06-12 17:30U:TRAWNews ReleaseTraws Pharma Provides Regulatory Update on Influenza Program
2026-05-27 08:45U:TRAWNews ReleaseTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
2026-05-15 07:00U:TRAWNews ReleaseTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
2026-05-08 07:30U:TRAWNews ReleaseTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
2026-04-15 16:01U:TRAWNews ReleaseTraws Pharma Reports Full Year 2025 Results and Provides Business Highlights
2026-04-15 08:15U:TRAWNews ReleaseTraws Pharma Announces Up to $60 Million Private Placement Financing
2026-02-19 07:30U:TRAWNews ReleaseTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
2026-01-26 08:30U:TRAWNews ReleaseTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
2026-01-13 07:00U:TRAWNews ReleaseTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID(TM)-Eligible and Ineligible COVID-19 Patients
2025-12-17 06:00U:TRAWNews ReleaseTraws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID(TM), Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
2025-11-13 07:00U:TRAWNews ReleaseTraws Pharma Reports Third Quarter 2025 Results and Business Highlights
2025-10-30 12:00U:TRAWNews ReleaseChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
2025-10-22 18:40U:TRAWNews ReleaseDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.